CRVS - Corvus Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CRVS is currently covered by 7 analysts with an average price target of $7.99. This is a potential upside of $4.31 (117.12%) from yesterday's end of day stock price of $3.68.

Corvus Pharmaceuticals's activity chart (see below) currently has 27 price targets and 36 ratings on display. The stock rating distribution of CRVS is 88.24% BUY and 11.76% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 60.71% with an average time for these price targets to be met of 311.88 days.

Highest price target for CRVS is $21, Lowest price target is $11, average price target is $12.13.

Most recent stock forecast was given by SEAN LEE from HC WAINWRIGHT on 26-Mar-2025. First documented stock forecast 05-Apr-2017.

Currently out of the existing stock ratings of CRVS, 15 are a BUY (88.24%), 2 are a HOLD (11.76%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$11

$7.39 (204.71%)

$11

1 months 24 days ago
(26-Mar-2025)

0/3 (0%)

$7.65 (228.36%)

Buy

$13

$9.39 (260.11%)

$8

6 months 7 days ago
(13-Nov-2024)

1/2 (50%)

$4.13 (46.56%)

1059

Buy

$3.5

6 months 28 days ago
(22-Oct-2024)

1/1 (100%)

$1.71 (95.53%)

134

Buy

$21

$17.39 (481.72%)

$12

8 months 4 days ago
(16-Sep-2024)

1/4 (25%)

$15.22 (263.32%)

216

Buy

$4

1 years 1 months 19 days ago
(01-Apr-2024)

3/4 (75%)

$2.36 (143.90%)

376

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CRVS (Corvus Pharmaceuticals) average time for price targets to be met?

On average it took 311.88 days on average for the stock forecasts to be realized with a an average price target met ratio 60.71

Which analyst has the current highest performing score on CRVS (Corvus Pharmaceuticals) with a proven track record?

ROBERT DRISCOLL

Which analyst has the current lower performing score on CRVS (Corvus Pharmaceuticals) with a proven track record?

GRAIG SUVANNAVEJH

Which analyst has the most public recommendations on CRVS (Corvus Pharmaceuticals)?

Robert Driscoll works at WEDBUSH and has 19 price targets and 10 ratings on CRVS

Which analyst is the currently most bullish on CRVS (Corvus Pharmaceuticals)?

Aydin Huseynov with highest potential upside - $17.39

Which analyst is the currently most reserved on CRVS (Corvus Pharmaceuticals)?

Mara Goldstein with lowest potential downside - -$0.11

Corvus Pharmaceuticals in the News

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants...

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?